Eyelid Position Interdependence in Involutional Ptosis Patients Submitted to 10% Phenylephrine

This study has been completed.
Information provided by:
University of Sao Paulo
ClinicalTrials.gov Identifier:
First received: March 17, 2009
Last updated: March 18, 2009
Last verified: March 2009
The primary aim of this study is to quantify eyelid position changes in tested and opposite eyes in ptosis patients submitted to 1, 2 or 4 drops of 10% phenylephrine in one eye. The secondary objective is to correlate the eye dominance, severity and laterality of ptosis with eyelid position changes in these 3 groups.


Study Type: Observational
Study Design: Observational Model: Cohort
Time Perspective: Prospective
Official Title: Comparative Study of Eyelid Position Interdependence in Involutional Ptosis Patients Submitted to 1, 2 or 4 Drops of 10% Phenylephrine

Resource links provided by NLM:

Further study details as provided by University of Sao Paulo:

Primary Outcome Measures:
  • Upper lid height before and after phenylephrine test lower lid height before and after phenylephrine test [ Time Frame: 3, 10, 15 and 30 minutes ] [ Designated as safety issue: Yes ]

Secondary Outcome Measures:
  • Scobee test to detect eye dominance [ Time Frame: 15 minutes before 10% phenylephrine instillation ] [ Designated as safety issue: Yes ]

Enrollment: 60
Study Start Date: September 2006
Study Completion Date: March 2009
Primary Completion Date: March 2009 (Final data collection date for primary outcome measure)
Patients submitted to application of 1 drop of 10% phenylephrine
Patients submitted to application of 2 drops of 10% phenylephrine
Patients submitted to application of 4 drops of 10% phenylephrine

Detailed Description:

This is a prospective observational study conducted in involutional ptosis patients, which will be submitted to instillation of a single drop of 10% phenylephrine in one eye(Group 1), 2 drops (G2) or 4 drops ( G3).

Video camera will record the images of both eyes before and after drug application at 3, 10, 15 and 30 minutes. The images will be edited to analyze upper and lower lid height.


Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Sampling Method:   Probability Sample
Study Population
Involutional blepharoptosis patients

Inclusion Criteria:

  • Involutional blepharoptosis
  • Upper Margin-reflex distance less or equal 2.0mm
  • Good fixation and collaboration

Exclusion Criteria:

  • Previous eyelid surgeries
  • Use of adrenergic or sympathicomimetics drugs
  • Myopathies
  • Thyroid orbitopathy
  • Non-controlled cardiovascular disease
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00864656

Ophthalmology Dept. University of Sao Paulo General Hospital
Sao Paulo, Brazil, 05403010
Sponsors and Collaborators
University of Sao Paulo
Principal Investigator: Suzana Matayoshi, MD Opthalmology Dept.Sao Paulo University General Hospital
  More Information

Responsible Party: Suzana Matayoshi, Clinica Oftalmologica HCFMUSP
ClinicalTrials.gov Identifier: NCT00864656     History of Changes
Other Study ID Numbers: phenylephrine test 
Study First Received: March 17, 2009
Last Updated: March 18, 2009
Health Authority: Brazil: Ethics Committee

Keywords provided by University of Sao Paulo:
adrenergic alpha-agonists
drug effects
diagnostic use

Additional relevant MeSH terms:
Eye Diseases
Eyelid Diseases
Adrenergic Agents
Adrenergic Agonists
Adrenergic alpha-1 Receptor Agonists
Adrenergic alpha-Agonists
Autonomic Agents
Cardiotonic Agents
Cardiovascular Agents
Molecular Mechanisms of Pharmacological Action
Nasal Decongestants
Neurotransmitter Agents
Peripheral Nervous System Agents
Pharmacologic Actions
Physiological Effects of Drugs
Protective Agents
Respiratory System Agents
Therapeutic Uses
Vasoconstrictor Agents

ClinicalTrials.gov processed this record on April 27, 2016